NI202100020A - Inhibidores de pde4 que contienen boro - Google Patents
Inhibidores de pde4 que contienen boroInfo
- Publication number
- NI202100020A NI202100020A NI202100020A NI202100020A NI202100020A NI 202100020 A NI202100020 A NI 202100020A NI 202100020 A NI202100020 A NI 202100020A NI 202100020 A NI202100020 A NI 202100020A NI 202100020 A NI202100020 A NI 202100020A
- Authority
- NI
- Nicaragua
- Prior art keywords
- boron
- pde4 inhibitors
- containing pde4
- formula
- pde4
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos que contienen boro de la Fórmula (I) X-Y-Z Fórmula (I) que inhiben la fosfodiesterasa 4 (PDE4). La invención también comprende composiciones farmacéuticas que contienen estos compuestos y métodos para tratar enfermedades, afecciones o trastornos que mejoran mediante la inhibición de PDE4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741868P | 2018-10-05 | 2018-10-05 | |
| US201962889599P | 2019-08-21 | 2019-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202100020A true NI202100020A (es) | 2021-08-24 |
Family
ID=68136492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202100020A NI202100020A (es) | 2018-10-05 | 2021-03-18 | Inhibidores de pde4 que contienen boro |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10946031B2 (es) |
| EP (1) | EP3861001B1 (es) |
| JP (1) | JP7048823B2 (es) |
| KR (1) | KR102576125B1 (es) |
| CN (1) | CN113166177A (es) |
| AU (1) | AU2019351960B2 (es) |
| BR (1) | BR112021005870B1 (es) |
| CA (1) | CA3114702C (es) |
| CL (1) | CL2021000843A1 (es) |
| CO (1) | CO2021003928A2 (es) |
| CR (1) | CR20210163A (es) |
| CU (1) | CU20210023A7 (es) |
| DK (1) | DK3861001T3 (es) |
| DO (1) | DOP2021000055A (es) |
| EC (1) | ECSP21023404A (es) |
| ES (1) | ES2974208T3 (es) |
| FI (1) | FI3861001T3 (es) |
| GE (1) | GEP20227442B (es) |
| IL (1) | IL282083A (es) |
| MA (1) | MA53808A (es) |
| MX (1) | MX2021003871A (es) |
| NI (1) | NI202100020A (es) |
| PE (1) | PE20211546A1 (es) |
| PH (1) | PH12021550743A1 (es) |
| SG (1) | SG11202102674RA (es) |
| TW (1) | TWI764052B (es) |
| UY (1) | UY38400A (es) |
| WO (1) | WO2020070651A1 (es) |
| ZA (1) | ZA202101822B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230069908A (ko) * | 2020-08-20 | 2023-05-19 | 화이자 인코포레이티드 | 1(r)-4-(5-(4-메톡시-3-프로폭시페닐)피리딘-3-일)-1,2-옥사보롤란-2-올의 안정한 국소 제제 |
| US20230340530A1 (en) | 2020-08-31 | 2023-10-26 | Pfizer Inc. | Methods of Protecting RNA |
| EP4269418A1 (en) | 2020-12-25 | 2023-11-01 | Reistone Biopharma Company Limited | Borate derivative and uses thereof |
| TW202408483A (zh) * | 2022-06-24 | 2024-03-01 | 大陸商瑞石生物醫藥有限公司 | 一種硼酸酯衍生物的可藥用鹽、其結晶形式及用途 |
| TW202404610A (zh) * | 2022-06-24 | 2024-02-01 | 大陸商瑞石生物醫藥有限公司 | 一種硼酸酯衍生物的結晶、其製備方法及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
| EP2343304B1 (en) * | 2005-02-16 | 2015-06-10 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| JP5745279B2 (ja) | 2008-01-09 | 2015-07-08 | アナコール ファーマシューティカルズ，インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
| BRPI0908565A2 (pt) * | 2008-03-06 | 2017-05-23 | Anacor Pharmaceuticals Inc | composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase |
| EP2187893A4 (en) | 2008-03-06 | 2012-02-22 | Anacor Pharmaceuticals Inc | SMALL BORON-CONTAINING MOLECULES AS ANTI-INFLAMMATORY AGENTS |
| TW201221131A (en) * | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| AU2012320382B2 (en) | 2011-10-07 | 2015-11-26 | Syngenta Participations Ag | Method for protecting useful plants or plant propagation material |
| HUE056251T2 (hu) * | 2012-10-25 | 2022-02-28 | Tetra Discovery Partners Llc | Heteroaril PDE4 inhibitorok |
| EP2752196A1 (en) | 2013-01-03 | 2014-07-09 | Université Bordeaux Segalen | Selective nox-1 inhibitor peptides and uses thereof |
| HUE034244T2 (en) | 2013-01-30 | 2018-02-28 | Agrofresh Inc | Use of benzoxaborols as volatile antimicrobial agents in meat, plants or plant parts |
| WO2014147009A1 (en) | 2013-03-18 | 2014-09-25 | Syngenta Participations Ag | Novel microbiocides |
| AU2014202928B1 (en) | 2013-06-05 | 2014-09-11 | Agrofresh Inc. | Compounds and compositions |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| EP3728230A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
-
2019
- 2019-10-01 CR CR20210163A patent/CR20210163A/es unknown
- 2019-10-01 KR KR1020217013141A patent/KR102576125B1/ko active IP Right Grant
- 2019-10-01 CU CU2021000023A patent/CU20210023A7/es unknown
- 2019-10-01 MX MX2021003871A patent/MX2021003871A/es unknown
- 2019-10-01 JP JP2021518191A patent/JP7048823B2/ja active Active
- 2019-10-01 PE PE2021000415A patent/PE20211546A1/es unknown
- 2019-10-01 BR BR112021005870-2A patent/BR112021005870B1/pt active IP Right Grant
- 2019-10-01 MA MA053808A patent/MA53808A/fr unknown
- 2019-10-01 CA CA3114702A patent/CA3114702C/en active Active
- 2019-10-01 ES ES19782756T patent/ES2974208T3/es active Active
- 2019-10-01 FI FIEP19782756.1T patent/FI3861001T3/fi active
- 2019-10-01 WO PCT/IB2019/058355 patent/WO2020070651A1/en active Application Filing
- 2019-10-01 DK DK19782756.1T patent/DK3861001T3/da active
- 2019-10-01 AU AU2019351960A patent/AU2019351960B2/en active Active
- 2019-10-01 EP EP19782756.1A patent/EP3861001B1/en active Active
- 2019-10-01 SG SG11202102674RA patent/SG11202102674RA/en unknown
- 2019-10-01 CN CN201980080149.6A patent/CN113166177A/zh active Pending
- 2019-10-01 GE GEAP201915599A patent/GEP20227442B/en unknown
- 2019-10-03 UY UY0001038400A patent/UY38400A/es not_active Application Discontinuation
- 2019-10-04 TW TW108135972A patent/TWI764052B/zh active
- 2019-10-04 US US16/593,171 patent/US10946031B2/en active Active
-
2020
- 2020-10-28 US US17/082,102 patent/US11559538B2/en active Active
-
2021
- 2021-03-18 NI NI202100020A patent/NI202100020A/es unknown
- 2021-03-18 ZA ZA2021/01822A patent/ZA202101822B/en unknown
- 2021-03-29 CO CONC2021/0003928A patent/CO2021003928A2/es unknown
- 2021-03-31 DO DO2021000055A patent/DOP2021000055A/es unknown
- 2021-04-05 IL IL282083A patent/IL282083A/en unknown
- 2021-04-05 CL CL2021000843A patent/CL2021000843A1/es unknown
- 2021-04-05 PH PH12021550743A patent/PH12021550743A1/en unknown
- 2021-04-05 EC ECSENADI202123404A patent/ECSP21023404A/es unknown
-
2022
- 2022-12-15 US US18/066,468 patent/US20230148402A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100020A (es) | Inhibidores de pde4 que contienen boro | |
| PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
| MX2020009782A (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso. | |
| NI201400121A (es) | Compuestos de indol e indazol que activan la ampk | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| BR112017006705A2 (pt) | inibidores de biossíntese de sulfato de heparan para o tratamento de doenças | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| EA201590268A1 (ru) | Ариллактамные ингибиторы киназы | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| MA42776B1 (fr) | Composés utiles pour l'inhibition du ror-gamma-t | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| EA201591369A1 (ru) | Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10) | |
| EA202190690A1 (ru) | Борсодержащие ингибиторы pde4 | |
| EA201891687A9 (ru) | Новые замещённые производные цианиндолина в качестве nik-ингибиторов | |
| MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam | |
| BR112017006798A2 (pt) | composto, composição farmacêutica, inibidor de tnap, métodos para o tratamento ou a profilaxia de uma doença ou condição e para a inibição de tnap, e, uso de um composto. | |
| MA39204A1 (fr) | Derives hétéroaryles inhibiteurs de vps34 et/ou de p13 pour le traitement de troubles proliferatifs, inflammatoires ou cardiovasculaires | |
| MX369236B (es) | Un compuesto para usarse en el tratamiento del transtorno de ansiedad comorbida y trastorno de depresion. | |
| MA35151B1 (fr) | Composés microarn et procédés pour la modulation de l'activité de mir-21 |